SNS Financial Group LLC cut its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 50.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,635 shares of the biopharmaceutical company’s stock after selling 5,788 shares during the quarter. SNS Financial Group LLC’s holdings in Bristol-Myers Squibb were worth $306,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. American National Bank lifted its stake in shares of Bristol-Myers Squibb by 36.0% in the 1st quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 508 shares during the period. Welch Investments LLC grew its position in shares of Bristol-Myers Squibb by 3.9% in the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares during the period. Crestwood Advisors Group LLC bought a new position in shares of Bristol-Myers Squibb in the 1st quarter worth about $116,000. Blue Chip Partners Inc. lifted its position in Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares during the period. Finally, State of Alaska Department of Revenue boosted its stake in Bristol-Myers Squibb by 2.8% during the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 60 shares in the last quarter. 68.88% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have commented on the company. Cowen and Company reissued a “hold” rating and issued a $65.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday. Jefferies Group LLC raised their price target on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 target price on the stock in a research note on Wednesday, July 12th. Hilliard Lyons downgraded Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price target on the stock. in a report on Tuesday, September 12th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $62.20.
Bristol-Myers Squibb Company (NYSE BMY) opened at 63.36 on Friday. The company has a 50 day moving average of $58.94 and a 200-day moving average of $56.02. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $63.55. The stock has a market capitalization of $103.91 billion, a price-to-earnings ratio of 23.14 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.69 earnings per share. On average, equities research analysts forecast that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be paid a $0.39 dividend. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.46%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.
In other news, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares in the company, valued at $1,006,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with our FREE daily email newsletter.